Population
Telmisartan bulk drug (active pharmaceutical ingredient - API)
Design
Other
Authors
Loading...
Alerts manufacturers to a dibromo impurity in telmisartan; leaves open its prevalence, toxicity, and need for limits.
This study successfully identified and characterized a synthetic route indicative impurity in the telmisartan active pharmaceutical ingredient.
Srinivasan et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: